ALFA Finder
Thu, 5 Nov
Molbio Diagnostics
H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.
Summary ready
Earnings calls
Molbio Diagnostics concalls
Every Molbio Diagnostics earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.
Outlook
Guides 25% FY27 top-line growth and a 24-25% EBITDA margin. H2 is expected to contribute about 60% of annual revenue.
Earlier call summaries
All →
10:14 IST
BSE
Earnings Call
Molbio Diagnostics Earnings Call Transcript: Key Takeaways
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
- Call
- Guides 25% growth
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,318.60
- Market cap
- ₹15,196 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- P/E (TTM)
- 98.4×Sector 54.5×
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.